•
Mar 31, 2021
Akero Q1 2021 Earnings Report
Akero Therapeutics reported first quarter financial results.
Key Takeaways
Akero Therapeutics reported its first quarter financial results, highlighting continued progress in developing treatments for non-alcoholic steatohepatitis (NASH).
Continued building on the strong foundation from the Phase 2a BALANCED main study.
New data showed signs of reversing fibrosis in biopsy-confirmed F4 NASH patients with compensated cirrhosis after 16 weeks of treatment.
Initiated two parallel, separate Phase 2b clinical trials in F2-F3 and F4 NASH this year.
Expect to begin reporting data in the third quarter of 2022.